Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Olanzapine for Injection, 10 mg/vial, Single-Dose Vial. Glenmark’s Olanzapine for Injection is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa2 IntraMuscular Injection 10 mg/vial, of Cheplapharm Registration GmbH [NDA 021253].
According to IQVIA sales data for the 12-month period ending May 2026, the Zyprexa IntraMuscular Injection market achieved annual sales of approximately $25.4 million.
Disclaimer: No Business Standard Journalist was involved in creation of this content
First Published: Jul 06 2026 | 9:32 AM IST
